CTMX

Cytomx Therapeutics Stock Analysis

AI Rating

Great
  • Quality4/10
  • Growth↑ 9/10
  • Momentum↑ 9/10
Cytomx Therapeutics sales and earnings growth
CTMX Growth
Great
  • Revenue Y/Y↓ -10.26%
  • EPS Y/Y↑ 141.18%
  • FCF Y/Y↑ 18.51%
Cytomx Therapeutics gross and profit margin trends
CTMX Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↑ 24.70%
  • ROIC↑ 60.40%
Cytomx Therapeutics net debt vs free cash flow
CTMX Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Cytomx Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗